

# Pavan K Bendapudi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2756179/publications.pdf>

Version: 2024-02-01

47  
papers

2,166  
citations

516561

16  
h-index

265120

42  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. <i>Blood Advances</i> , 2022, 6, 2835-2846.	2.5	8
2	When Is It Preferable to Use Warfarin?. , 2022, 1, .		0
3	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. <i>Blood</i> , 2021, 137, 969-976.	0.6	46
4	Factor V Deficiency (Owren's Disease) in a Patient at High Risk for Transfusion-Associated Circulatory Overload and Bleeding During Laser Lead Extraction. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	1
5	Case 7-2021: A 19-Year-Old Man with Shock, Multiple Organ Failure, and Rash. <i>New England Journal of Medicine</i> , 2021, 384, 953-963.	13.9	5
6	Accurate accounting of caplacizumab cost effectiveness. <i>Lancet Haematology</i> ,the, 2021, 8, e315.	2.2	3
7	Severe autoimmune hemolytic anemia following receipt of <scp>SARSâ€CoV</scp>â€2 <scp>mRNA</scp> vaccine. <i>Transfusion</i> , 2021, 61, 3267-3271.	0.8	29
8	Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. <i>Blood</i> , 2021, 138, 745-745.	0.6	1
9	Assessing the risk of refractory disease in iTTP. <i>British Journal of Haematology</i> , 2020, 191, 143-144.	1.2	0
10	Injury measurements improve interpretation of thrombus formation data in the cremaster arteriole laserâ€induced injury model of thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3078-3085.	1.9	8
11	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020, 136, 489-500.	0.6	1,021
12	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 365.	0.9	2
13	Cationic zinc is required for factor XII recruitment and activation by stimulated platelets and for thrombus formation in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2318-2328.	1.9	12
14	Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. <i>Transfusion</i> , 2020, 60, 841-846.	0.8	16
15	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	0.5	46
16	Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
17	Rare Inherited Defects of the Complement System in Purpura Fulminans. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
18	Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , 2019, 3, 1512-1518.	2.5	34

#	ARTICLE	IF	CITATIONS
19	PC240. Surface Activation of Factor XII by Activated Platelets Contributes to Arterial Thrombus Formation. <i>Journal of Vascular Surgery</i> , 2019, 69, e270-e271.	0.6	1
20	Utilizing a <sc>PLASMIC</sc> scoreâ€based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard <sc>TMA</sc> Research Collaborative. <i>British Journal of Haematology</i> , 2019, 186, 490-498.	1.2	20
21	Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies. <i>Blood</i> , 2019, 134, 1075-1075.	0.6	4
22	Perioperative management of a redo aortic root replacement in a patient with severe factor XI deficiency. <i>Journal of Cardiac Surgery</i> , 2018, 33, 86-89.	0.3	5
23	Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis. <i>Transfusion Medicine Reviews</i> , 2018, 32, 69-76.	0.9	67
24	Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. <i>Blood Advances</i> , 2018, 2, 2917-2921.	2.5	9
25	Predictors of Relapse and Efficacy of Rituximab in Autoimmune Thrombotic Thrombocytopenic Purpura (TTP): A Multi-Institutional Registry-Based Analysis. <i>Blood</i> , 2018, 132, 375-375.	0.6	1
26	Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. <i>Lancet Haematology</i> , 2017, 4, e157-e164.	2.2	338
27	Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency. <i>Transfusion</i> , 2017, 57, 2151-2158.	0.8	4
28	Clinical Scoring Systems in Thrombotic Microangiopathies. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 540-548.	1.5	21
29	Local and Systemic Changes Associated with Long-term, Percutaneous, Static Implantation of Titanium Alloys in Rhesus Macaques (). <i>Comparative Medicine</i> , 2017, 67, 165-175.	0.4	9
30	Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity scoreâ€matched study. <i>Transfusion</i> , 2016, 56, 2069-2077.	0.8	26
31	A substrate-driven allosteric switch that enhances PDI catalytic activity. <i>Nature Communications</i> , 2016, 7, 12579.	5.8	98
32	Bench to bedside: the challenge and promise of translating basic research discoveries in thrombotic microangiopathies. <i>Transfusion</i> , 2016, 56, 1675-1677.	0.8	1
33	An Algorithmic Approach to the Diagnosis and Management of the Thrombotic Microangiopathies. <i>American Journal of Clinical Pathology</i> , 2016, 145, 152-154.	0.4	10
34	Extracellular Thiol Isomerases and Their Role in Thrombus Formation. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 1-15.	2.5	59
35	Utilization and Cost Effectiveness of a Risk Stratified Diagnostic Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2016, 128, 1456-1456.	0.6	2
36	Stimulated Platelets but Not Endothelium Generate Thrombin Via a Factor XIIa-Dependent Mechanism Requiring Phosphatidylserine Exposure. <i>Blood</i> , 2016, 128, 258-258.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Coagulation Biomarkers in Healthy Chinese-Origin Rhesus Macaques ( <i>Macaca mulatta</i> ). <i>Journal of the American Association for Laboratory Animal Science</i> , 2016, 55, 252-9.	0.6	1
38	Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. <i>British Journal of Haematology</i> , 2015, 171, 836-844.	1.2	73
39	Therapeutic Plasma Exchange for the Treatment of Thrombotic Microangiopathy without Severe ADAMTS13 Deficiency: A Propensity Score-Matched Study. <i>Blood</i> , 2015, 126, 3471-3471.	0.6	1
40	Derivation and Prospective Validation of a Predictive Score for the Rapid Diagnosis of Thrombotic Thrombocytopenic Purpura: The Plasmic Score. <i>Blood</i> , 2014, 124, 231-231.	0.6	17
41	ML359, a Small Molecule Inhibitor of Protein Disulfide Isomerase That Prevents Thrombus Formation and Inhibits Oxidoreductase but Not Transnitrosylase Activity. <i>Blood</i> , 2014, 124, 2880-2880.	0.6	2
42	Regulation of Protein Disulfide Isomerase By S-Nitrosylation Controls Its Function during Thrombus Formation. <i>Blood</i> , 2014, 124, 93-93.	0.6	0
43	Moderate Deficiency of ADAMTS13 in Thrombotic Microangiopathy Is Associated with Poor Survival Regardless of Plasma Exchange. <i>Blood</i> , 2014, 124, 4193-4193.	0.6	0
44	Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation. <i>Science Translational Medicine</i> , 2011, 3, 103ra99.	5.8	38
45	18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. <i>Cancer Biology and Therapy</i> , 2008, 7, 1947-1951.	1.5	14
46	Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. <i>PLoS ONE</i> , 2008, 3, e2125.	1.1	74
47	Getting at MYC through RAS. <i>Clinical Cancer Research</i> , 2005, 11, 4278-4281.	3.2	36